The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase–5 inhibitors
Author:
Open Access
- 1 January 2014
- journal article
- review article
- Published by Polskie Towarzystwo Urologiczne in Central European Journal of Urology
- Vol. 67 (3) , 314-8
Abstract
Benign prostate hyperplasia and erectile dysfunction affect a significant subset of men. BPH and ED may have the same promoting conditions and are the strong predicting risk factors to each other. A significant number of these patients are bothered by lower urinary tract symptoms (LUTS). Direct correlation of age, sexual dysfunction and LUTS severity has been well documented. Many sexually dysfunctional patients with concomitant BPH receive alpha-adrenergic antagonists and any Phosphodiesterase-5 (PDE5) inhibitor simultaneously. PDE5 inhibitors relieve LUTS symptoms in the course of BPH and reduce independent detrusor contractions. This paper presents the results of clinical trials on the efficacy of PDE5 inhibitors on LUTS, new perspectives on its use and newly-identified side effects. The review is based on an internet search of PubMed and Medscape databases. The search terms were as follows: LUTS and ED, BPH and phosphodiesterase-5 inhibitors, LUTS clinical trials, phosphodiesterase-5 inhibitors mechanisms. Clinical trials show an epidemiological and pathophysiological relationship between BPH, LUTS and ED. Numerous studies reveal the alleviating effect of phosphodiesterase-5 inhibitors on LUTS, expressed as the reduction of IPSS score, but not followed by a change in Qmax. Opponents raise a link of PDE5 inhibitors with increased risk of melanoma. New studies reveal that phosphodiesterase-5 inhibitors are effective in the treatment of neurological disorders. Researches reveal the efficacy of phosphodiesterase-5 inhibitors in LUTS along with an improvement of erectile function. The molecular mechanism of action of such drugs suggests imminent novel applications. Potential benefits will be multidimensional. Unfortunately, interfering with particular molecular mechanisms may alleviate some diseases, but may lay groundwork for others - new and even more devastating.Keywords
This publication has 39 references indexed in Scilit:
- Mechanism of Action of PDE5 Inhibitors in LUTS and ED: the NO–cGMP PathwayEuropean Urology, 2009
- The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 InhibitorsEuropean Urology, 2009
- Pre‐clinical evidence for the use of phosphodiesterase‐5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptomsBJU International, 2006
- Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculationUrology, 2006
- Summary of the Recommendations on Sexual Dysfunctions in MenThe Journal of Sexual Medicine, 2004
- Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in BrazilUrology, 2003
- CHARACTERIZATION AND FUNCTIONAL RELEVANCE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOENZYMES OF THE HUMAN PROSTATEJournal of Urology, 2001
- Management of Symptomatic BPH in the US: Who Is Treated and How?European Urology, 1999
- Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxideThe Prostate, 1997
- Heme oxygenase and NO-synthase in the human prostate – relation to adrenergic, cholinergic and peptide-containing nervesJournal of the Autonomic Nervous System, 1997